Biblioteca Humberto Rosselli Quijano
Información del autor
Autor John A. Engh |
Documentos disponibles escritos por este autor (1)
Refinar búsqueda
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions / Astrid B. Birkenaes en Journal of Clinical Psychopharmacology, Año 2008 - Vol. 28 - No. 2 (Abril)
[artículo]
Título : Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions Tipo de documento: texto impreso Autores: Astrid B. Birkenaes, Autor ; Kåre I. Birkeland, Autor ; John A. Engh, Autor Fecha de publicación: 2023 Artículo en la página: pp. 132-137 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Benzodiacepinas, Índice de masa corporal, Clozapina, Terapia con medicamentos, Dislipidemias, Hipertensión, Síndrome metabólico, Obesidad, Trastornos psicóticos, Esquizofrenia. Resumen: Antipsychotic (AP) treatment, in particular with some second-generation drugs, is associated with weight gain and other metabolic side effects. However, the relationship between drug-induced weight gain and dyslipidemia is not well understood. We investigated how cardiometabolic risk factors were related to body mass during treatment with different APs under real-life conditions. Link: ./index.php?lvl=notice_display&id=30855
in Journal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 2 (Abril) . - pp. 132-137[artículo] Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions [texto impreso] / Astrid B. Birkenaes, Autor ; Kåre I. Birkeland, Autor ; John A. Engh, Autor . - 2023 . - pp. 132-137.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2008 - Vol. 28 - No. 2 (Abril) . - pp. 132-137
Palabras clave: Antipsicóticos, Benzodiacepinas, Índice de masa corporal, Clozapina, Terapia con medicamentos, Dislipidemias, Hipertensión, Síndrome metabólico, Obesidad, Trastornos psicóticos, Esquizofrenia. Resumen: Antipsychotic (AP) treatment, in particular with some second-generation drugs, is associated with weight gain and other metabolic side effects. However, the relationship between drug-induced weight gain and dyslipidemia is not well understood. We investigated how cardiometabolic risk factors were related to body mass during treatment with different APs under real-life conditions. Link: ./index.php?lvl=notice_display&id=30855